Abstract:Background and Aim: Glioma is one of the most prevalent and refractory brain cancers with a high recurrence rate. Current limitations of experimental in vitro models include their inability to remodel the heterogeneity of the parental tumors and their incapacity to effectively reflect antitumor effects and mechanisms observable in vivo. Organoid models, as a new technology developed in recent years, can preserve the histological characteristics, cellular diversity, and gene expression of parental tumors to the fullest extent, thereby delivering more reliable data. This study intends to construct a simple organoid model developed from glioma patient material. Materials and Methods: Glioma samples were taken intraoperatively and cultured in the organoid medium using a continuous horizontal shaker. Sample collection and scientific research were authorized and approved by the Ethics Committee of Kowloon Hospital, China (Approval No. KY-2021-007). Immunofluorescence was applied to identify CD31 and Sox2 protein expression in the organoid model. The differences between primary glioblastomas and transplanted organoid tumors were analyzed by hematoxylin and eosin (H and E) staining. Immunohistochemistry (IHC) and Western blot assay were used to analyze the Sox2, Ki67, and CD31 protein expression levels. Results: The success rate of establishing organoid models was 90.9% in the primary glioblastomas, 75.0% in the WHO Grade III gliomas, and 42.9% in the Grade I–II gliomas. Immunofluorescence demonstrated that in vitro cultured organoids expressed CD31 and Sox2. Similarly, IHC and Western blot assay showed that orthotopically transplanted organoid tumors could exhibit high expressions of Sox2, Ki67, and CD31. There were no significant differences regarding the pathological features of primary glioblastomas and glioma organoid model as judged by H and E staining. Conclusions: This study presents a simple in vitro organoid model established from glioma patient samples. The success rate of constructing an organoid model is correlated with the degree of glioma malignancy. The established organoid model displays original model properties and simplifies the development of new experimental platforms that can support preclinical glioma treatment studies.

Novel Organoid Construction Strategy for Non-Involuting Congenital Hemangioma for Drug Validation

Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation

Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses

CD133 Selected Stem Cells from Proliferating Infantile Hemangioma and Establishment of an in Vivo Mice Model of Hemangioma

A novel in vivo model of human hemangioma: xenograft of human hemangioma tissue on nude mice.

Organoids: opportunities and challenges of cancer therapy

Infantile hemangioma models: is the needle in a haystack?

Establishment and Validation of Glioma Patient-Derived Organoid Models

A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening

Cancer Patient Tissueoid with Self-Homing Nano-Targeting of Metabolic Inhibitor

Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification

Intrahepatic cholangiocarcinoma-derived organoids for disease modelling and drug screening

Establishment and Molecular Characterization of Patient-Derived Organoids for Primary Central Nervous System Lymphoma

Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma

Organoids: approaches and utility in cancer research

In vivo development and single‐cell transcriptome profiling of human brain organoids

Establishment of Organoid Models Based on a Nested Array Chip for Fast and Reproducible Drug Testing in Colorectal Cancer Therapy

Drug Discovery Via Human-Derived Stem Cell Organoids.

MDB-25. ESTABLISHING A NOVEL CEREBELLAR ORGANOID MODEL FOR INVESTIGATING HEREDITARY PREDISPOSITION TO CHILDHOOD BRAIN CANCER